| Comparison of metabolic and prolactin variables from a six-month randomised trial of olanzapine and quetiapine in schizophrenia. | |
| | |
MedLine Citation:
|
PMID: 19240085 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Schizophrenia patients have a potential increased risk of metabolic dysregulation during antipsychotic treatments. Our objective was to compare changes in prolactin and metabolic variables (glucose, lipids and weight) as a post-hoc analysis from a six-month, randomised, controlled study of olanzapine (OLZ, n = 171; 10-20 mg/day) or quetiapine (QUE, n = 175; 300-700 mg/day). No statistically significant treatment group differences for baseline to endpoint mean changes in body mass index (P = 0.209) or weight (P = 0.250) were observed. There was a greater incidence of clinically significant weight gain (defined as > or =7% increase from baseline) in OLZ (19.2%) compared to QUE (13.2%)-treated patients (P = 0.181). No statistically significant treatment group differences for lipids and glucose variables, either as mean change from baseline to endpoint or treatment-emergent (TE) categorical changes were found (P > or = 0.05). Incidence rates for TE diabetes were similar between treatment groups 2.5% (n = 4) in the OLZ-treatment group and 1.3% (n = 2) in the QUE-treatment group (P = 0.685). Hyperprolactinaemia was present at baseline in many patients (OLZ 32.9%; QUE 31.4%), but after 2 weeks of treatment prolactin values had reverted to normal for nearly all patients (OLZ 100%; QUE 99.4%). There were no significant treatment differences in any variable between cohorts. |
| | |
Authors:
|
C Bushe; J Sniadecki; A J Bradley; V Poole Hoffmann |
Related Documents
:
|
12725705 - Addition of rosiglitazone to existing sulfonylurea treatment in chinese patients with t... 10361905 - Secondary prevention with lipid lowering therapy in familial hypercholesterolemia: a co... 6420965 - Long-term treatment of onchocerciasis patients from the liberian rain-forest with low d... 16382385 - Pregnancy-associated spontaneous coronary artery dissection: impact of medical treatmen... 20695925 - An exploratory analysis of factors associated with weight change in a 16-week trial of ... 2022825 - Palmaris brevis turnover flap as an adjunct to internal neurolysis of the chronically s... |
Publication Detail:
|
Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial Date: 2009-02-24 |
Journal Detail:
|
Title: Journal of psychopharmacology (Oxford, England) Volume: 24 ISSN: 1461-7285 ISO Abbreviation: J. Psychopharmacol. (Oxford) Publication Date: 2010 Jul |
Date Detail:
|
Created Date: 2010-06-17 Completed Date: 2010-09-16 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8907828 Medline TA: J Psychopharmacol Country: United States |
Other Details:
|
Languages: eng Pagination: 1001-9 Citation Subset: IM |
Affiliation:
|
Eli Lilly and Company, Basingstoke, UK. bushe_chris@lilly.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Antipsychotic Agents / adverse effects*, therapeutic use* Benzodiazepines / adverse effects*, therapeutic use* Blood Glucose / metabolism Body Mass Index Body Weight Dibenzothiazepines / adverse effects*, therapeutic use* Double-Blind Method Female Humans Lipid Metabolism / drug effects, physiology Male Middle Aged Prolactin / blood* Psychotic Disorders / blood, drug therapy, psychology Schizophrenia / blood, drug therapy*, metabolism* Schizophrenic Psychology Weight Gain / drug effects |
| Chemical | |
Reg. No./Substance:
|
0/Antipsychotic Agents; 0/Blood Glucose; 0/Dibenzothiazepines; 0/quetiapine; 12794-10-4/Benzodiazepines; 132539-06-1/olanzapine; 9002-62-4/Prolactin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Trends in the prevalence and incidence of diabetes in the UK: 1996-2005.
Next Document: Antidepressants that inhibit neuronal norepinephrine reuptake are not associated with increased spon...